BMS, Amgen scramble for Kendall Square space; More Ranbaxy execs ship out; Eisai files for new Fycompa use in EU;

@FiercePharma: Top-read on FP Tues: Big Pharma doesn't win the margin stakes. That's Jazz, Celgene, Regeneron and Alexion. Report | Follow @FiercePharma

@TracyStaton: Been on vacay? @FiercePharma's top August news so far: Pfizer faces growing legal threat over Lipitor. More | Follow @TracyStaton

@EricPFierce: FDA warning letter for India's Marck Biosciences lays out in vivid detail why it banned it plant. Article | Follow @EricPFierce

@CarlyHFierce: Merck taps celeb chef to deliver diabetes message to Hispanics. Story | Follow @CarlyHFierce

> It's a game of real estate musical chairs for Bristol-Myers Squibb ($BMY), Amgen ($AMGN) and an unidentified biotech, all seeking big blocks of space in Cambridge, MA's Kendall Square area. Report

> Ranbaxy Laboratories, the embattled Indian generics maker, lost another two senior managers, including global HR chief Sandeep Girotra. Report

> Eisai asked European regulators to approve a new use for its seizure drug Fycompa, as an add-on treatment for Primary generalized tonic-clonic seizures. Release

> A shake-up at the top of drugstore giant Walgreen ($WAG) followed a misguided estimate for Medicare Part D revenues, which ended up forcing the company to cut its 2014 forecast by more than $1 billion. Report (sub. req.)

> Jordan-based Hikma Pharmaceuticals cut its 2014 revenue forecast thanks to unrest in the Middle East, which is interfering with sales. Report

Medical Device News

@FierceMedDev: VC Rock Health partners with Abbott, expands digital health portfolio. Story | Follow @FierceMedDev

@StacyALawrence: Abbott gets $20M from DoD to develop portable concussion test. More | Follow @StacyALawrence

@VarunSaxena2: ICYMI: FDA targets off-label use of intranasal splint, with safety alert and Class I recall notice. Article | Follow @VarunSaxena2

@EmilyWFierce: Scientists at Biomeme developing a portable, real-time PCR machine that runs lab tests through a smartphone. Story via Wired | Follow @EmilyWFierce

> Boston Sci to develop two new guidewires with cardiological indications by 2015. Story

> Survey says people want neurological diagnosis, regardless of cure. More

> ConvaTec weighs plans for inversion deal amid rumors of 2015 sale. Article

Biotech News

@FierceBiotech: Sanofi wins FDA's blessing for an oral Gaucher drug. News | Follow @FierceBiotech

@JohnCFierce: Top trending story, 2 days now: Novo chief Sorensen preps for showdown as Lilly's dulaglutide nears diabetes market. Report | Follow @JohnCFierce

@DamianFierce: $FOLD CEO on positive new migalastat data, next-gen Fabry treatment and the importance of perseverance. Report | Follow @DamianFierce

@EmilyMFierce: Viral inducers plus antibodies thwart latent HIV in mice. FierceBiotech Research story | Follow @EmilyMFierce

> AstraZeneca's new antibiotic comes through in Phase III. Item

> Bristol-Myers, Celgene plan to match an immuno-oncology star with a rising chemotherapy. Story

> Could buying Salix get Valeant off of Allergan's scent? More

Drug Delivery News

> Hydrogel enables longer graft survival in hand, leg transplant patients. Article

> Russian scientists close in on drug-delivering nanorobots. Story

> Study finds blood-brain barrier opening can be controlled, enabling enhanced drug delivery. More

> Mist formulation of Boehringer Ingelheim's COPD inhaler gets advisory committee nod. Story

> Scientists uncover new drug delivery method using nanosecond lasers and carbon nanotubes. Article

Diagnostics News

> Blood test for drug-resistant malaria strain shows promise. Report

> Two tests better than one to spot harmful mold infection. Story

> Cancer Genetics boosts Medicare coverage for DNA-based cancer Dx. More

> LabCorp jumps into prenatal Dx market already packed with rivals. Story

> Investors become ambivalent to Biocept's Dx commercialization plans. Article

Pharma Marketing News

> Celgene cost-sharing deal sways NICE to greenlight new Revlimid use. News

> When is 5 years not 5 years? When it's the FDA counting, Eisai claims. Report

> AbbVie aims to truck ahead with hep C testing promo campaign. More

> Hardest-charging drugs this year? They're not just Sovaldi and Olysio. Story

> Skeptical U.K. watchdogs decide to back Gilead's hep C star Sovaldi. Article

And Finally... Does your dog need training to run with you? No, but a good diet doesn't hurt. Report

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.